SGLT-2 Inhibitors for the Treatment of Type 2 Diabetes Mellitus

Raymond A Plodkowski(University of California San Diego), Quang Nguyen(University of Nevada, Reno), Megan E. McGarvey(VA Sierra Nevada Health Care System), Keith Reisinger‐Kindle(VA Sierra Nevada Health Care System), Mordecai Solomon(VA Sierra Nevada Health Care System), Heather M. Huribal(VA Sierra Nevada Health Care System), Bradley Kramer(VA Sierra Nevada Health Care System)

Touro Scholar (Touro College)

January 1, 2015

Cited by 2

Related Papers

American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care of Patients with Obesity

|Endocrine Practice|2016|1.8k

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

|The Lancet|2010|1k

Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes

|Diabetes Care|2013|494

American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity

|Endocrine Practice|2016|275

Serum 25-hydroxyvitamin D concentrations in relation to cardiometabolic risk factors and metabolic syndrome in postmenopausal women

|American Journal of Clinical Nutrition|2011|137